RLHomo sapiens (Human)Cancer cell line

Also known as: RL-2261 (Based on the ATCC catalog number.), RL2261 (Based on the ATCC catalog number.), CRL

🤖 AI SummaryBased on 12 publications

RL Cell Line

Quick Overview

RL is a human B-cell lymphoma cell line used in cancer research.

Detailed Summary

The RL cell line is a human B-cell lymphoma cell line derived from a patient with transformed follicular lymphoma. It is widely used in research to study the mechanisms of cancer progression and drug sensitivity. RL has been utilized in studies investigating the effects of proteasome inhibitors like bortezomib and in genomic analyses to identify mutations and copy number variations associated with lymphoma. This cell line is part of several large-scale studies, including the Cancer Cell Line Encyclopedia (CCLE) and the Catalogue of Somatic Mutations in Cancer (COSMIC), providing valuable data for understanding the genetic basis of lymphoma. Research on RL has contributed to the identification of key mutations and pathways involved in lymphoma development and treatment resistance.

Research Applications

Study of proteasome inhibitor sensitivityGenomic and transcriptomic analysisInvestigation of mutation patterns in lymphomaDrug response profiling

Key Characteristics

Used in studies of B-cell lymphomaPart of large cancer cell line databasesRelevant for understanding lymphoma genetics

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1660
Species	Homo sapiens (Human)
Tissue Source	Ascites[UBERON:UBERON_0007795]

Donor Information

Age	52
Age Category	Adult
Sex	Male
Race	caucasian

Disease Information

Disease	Diffuse large B-cell lymphoma
Lineage	Lymphoid
Subtype	Diffuse Large B-Cell Lymphoma, NOS
OncoTree Code	DLBCLNOS

DepMap Information

Source Type	ATCC
Source ID	ACH-000371_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Ala138Pro (c.412G>C)	Homozygous	-	Unknown, Unknown, PubMed=17363600

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

D13S317

D16S539

D18S51

D19S433

13,14

D21S11

29,30

D2S1338

17,20

D3S1358

16,17

D5S818

D7S820

10,13

D8S1179

12,14

FGA

23,24

Penta D

Penta E

12,17

TH01

9,10

TPOX

9,11

vWA

19,20

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOI PubMed PMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOI PubMed PMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

Genetic heterogeneity of diffuse large B-cell lymphoma.";

Dunson D.B., Dave S.S.

Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.

Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.

Int. J. Cancer 125:212-221(2009).

DOI PubMed

Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma.

Young B.D.

Leukemia 21:1514-1520(2007).

DOI PubMed

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Schenkein D., Lister T.A., Joel S.P.

Cancer Res. 67:2783-2790(2007).

DOI PubMed

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.

Martinez-Climent J.A.

Blood 109:271-280(2007).

DOI PubMed

Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines.

Beckwith M., Longo D.L., O'Connell C.D., Moratz C.M., Urba W.J.

J. Natl. Cancer Inst. 82:501-509(1990).

DOI PubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Web Resources

tcpaportal.org